| Investigating Meningococcal Vaccines in Adults (NCT02398396) | University of Oxford | 2015-04-01 |
| Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age (NCT01978093) | GlaxoSmithKline | 2014-02-01 |
| Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) (NCT01839188) | MCM Vaccines B.V. | 2013-05-01 |
| Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination (NCT01839175) | Sanofi Pasteur, a Sanofi Company | 2013-04-01 |
| Neisseria Meningitidis Burden of Disease Study (NCT01730391) | GlaxoSmithKline | 2013-01-01 |
| Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (NCT01553279) | MCM Vaccines B.V. | 2012-03-30 |
| NeisVac-C Single Prime Study in Infants (NCT01218451) | Pfizer | 2010-09-01 |
| Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants (NCT01090453) | GlaxoSmithKline | 2010-05-17 |
| Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants (NCT00871338) | GlaxoSmithKline | 2009-06-24 |
| Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines (NCT00891176) | GlaxoSmithKline | 2009-05-14 |
| Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. (NCT00871741) | GlaxoSmithKline | 2009-04-01 |
| Dose Comparison Study of Menactra® in US Children (NCT00700635) | Sanofi Pasteur, a Sanofi Company | 2008-06-01 |
| Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants (NCT00586612) | GlaxoSmithKline | 2007-12-01 |
| Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. (NCT00345683) | GlaxoSmithKline | 2007-07-01 |
| Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine (NCT00454987) | GlaxoSmithKline | 2007-05-16 |
| Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia (NCT00444951) | Sanofi Pasteur, a Sanofi Company | 2007-02-01 |
| Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age (NCT00345579) | GlaxoSmithKline | 2006-09-01 |
| Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB (NCT00359983) | GlaxoSmithKline | 2006-09-01 |
| Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. (NCT00326118) | GlaxoSmithKline | 2006-06-01 |
| Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC (NCT00322335) | GlaxoSmithKline | 2006-05-01 |
| Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine (NCT00327184) | GlaxoSmithKline | 2006-04-01 |
| Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines (NCT00134719) | GlaxoSmithKline | 2005-04-11 |
| Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 (NCT00263653) | GlaxoSmithKline | 2005-03-01 |
| Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine (NCT00258700) | GlaxoSmithKline | 2005-02-01 |
| Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults (NCT00197795) | Public Health England | 2005-01-01 |
| Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects (NCT00323050) | GlaxoSmithKline | 2004-11-01 |
| Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine (NCT00129129) | GlaxoSmithKline | 2004-08-01 |
| Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine (NCT00127855) | GlaxoSmithKline | 2003-03-01 |
| Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine (NCT00772070) | Sanofi Pasteur, a Sanofi Company | 2003-03-01 |
| 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age (NCT00129116) | GlaxoSmithKline | 2003-03-01 |